Diabetic Gastroparesis Treatment Market to Grow with a CAGR of 3.23% through 2028
Rising focus on innovative therapies and interventions
are expected to drive the Global Diabetic Gastroparesis Treatment Market growth
in the forecast period, 2024-2028.
According to TechSci Research report, “Diabetic
Gastroparesis Treatment Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the Global Diabetic
Gastroparesis Treatment Market stood at USD 2.89 billion in 2022 and is
anticipated to grow with a CAGR of 3.23% in the
forecast period, 2024-2028. The Global Diabetic Gastroparesis Treatment Market
is experiencing significant growth, driven by a confluence of factors that
underscore the pressing need for effective solutions in managing this
debilitating condition. One of the
primary drivers fueling the growth of the Diabetic Gastroparesis Treatment
Market is the escalating prevalence of diabetes worldwide. Diabetes,
particularly type 1 and type 2, has reached epidemic proportions, affecting
millions of individuals globally. A significant subset of diabetes patients,
approximately 20%, experiences gastroparesis as a complication.
As the diabetic population continues to expand, the
incidence of diabetic gastroparesis rises in tandem, increasing the demand for
treatments and management strategies. Awareness about gastroparesis has grown
substantially in recent years. More healthcare professionals are recognizing
the condition and its impact on diabetes management. Consequently, there has
been a surge in the diagnosis of gastroparesis cases, leading to an increased
demand for effective treatments. Patients are now more likely to seek medical
attention for their gastrointestinal symptoms, driving the market for
gastroparesis treatments.
Medical devices have emerged as a crucial component of
gastroparesis management, especially for patients who do not respond well to
medications alone. Gastric electrical stimulators (GES) are at the forefront of
technological innovations in this regard. These devices can modulate stomach
electrical activity, improving gastric motility and alleviating symptoms. As
technology continues to advance, GES and other medical devices are becoming
more efficient, durable, and minimally invasive, making them more attractive
options for both patients and healthcare providers. Pharmaceutical companies
are investing heavily in research and development to create novel medications
specifically designed to treat diabetic gastroparesis. Prokinetic agents, which
enhance stomach motility, and antiemetics, which control nausea and vomiting,
are key areas of focus. Several promising drug candidates are currently in
clinical trials, and their successful development could revolutionize
gastroparesis treatment. These advancements are propelling market growth and
offering hope to patients who have limited options for symptom management.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Diabetic
Gastroparesis Treatment Market.”
Furthermore, advocacy organizations and healthcare
professionals are working tirelessly to raise awareness about the importance of
regular check-ups and monitoring for lipodystrophy among HIV-positive patients.
This heightened awareness is instrumental in reducing the prevalence of severe
cases and promoting early intervention. The Global Diabetic Gastroparesis
Treatment Market benefits from a shift toward more comprehensive and
multidisciplinary care approaches. Managing lipodystrophy requires a holistic
approach, involving a diverse team of healthcare professionals, including
endocrinologists, infectious disease specialists, dietitians, and mental health
experts.
The Global Diabetic Gastroparesis Treatment Market is
segmented into Type, Route of Administration, Distribution Channel, Regional
Distribution, And Company.
Based on the Drug Class, the Gastroprokinetic agents
emerged as the dominant segment in the global market for Global Diabetic
Gastroparesis Treatment Market in 2022., Gastroprokinetic agents are the
primary medications prescribed for diabetic gastroparesis because they directly
address the underlying issue of delayed stomach emptying. These agents work by
enhancing the motility of the gastrointestinal tract, promoting coordinated
contractions, and facilitating the passage of food from the stomach into the
small intestine. This action helps alleviate the core symptoms of
gastroparesis, including nausea, vomiting, and abdominal discomfort, which
significantly affect patients' quality of life.
Based on the Route of Administration, the oral segment
emerged as the dominant player in the global market for Global Diabetic
Gastroparesis Treatment Market in 2022.
Oral medications are typically more convenient and
comfortable for patients. They can be taken as tablets or capsules, which are
easy to swallow and integrate into a patient's daily routine. This convenience
promotes better medication adherence, ensuring that patients consistently take
their prescribed treatments. Many of the medications commonly used to manage
diabetic gastroparesis, such as gastroprokinetic agents (e.g., metoclopramide),
antiemetic agents (e.g., ondansetron), and antihistamines (e.g.,
diphenhydramine), are available in oral formulations. This availability of oral
options provides healthcare providers with a range of choices to tailor
treatment plans to individual patient needs.
Compared to parenteral (injection) or nasal
administration methods, oral medications are less invasive. Injections may be
uncomfortable or intimidating for some patients, potentially leading to
decreased treatment compliance. Nasal administration can also be less
comfortable and may cause irritation in some individuals.
Based on the
Distribution Channel, the Retail Pharmacies segment emerged as the dominant
player in the global market for Global Diabetic Gastroparesis Treatment Market
in 2022. Retail pharmacies are widely accessible to the general population,
making it convenient for patients to obtain their prescribed medications. They are
typically located in urban and suburban areas, allowing patients to fill their
prescriptions without the need for extensive travel. Patients are often
familiar with their local retail pharmacies, which builds trust and confidence
in the products and services provided. Many individuals have established
relationships with pharmacists and staff at these locations, enhancing the
overall patient experience.
North America emerged as the dominant player in the
global Diabetic Gastroparesis Treatment Market
in 2022, holding the largest market share. the region has a high
prevalence of diabetes, which naturally leads to a larger population at risk of
developing diabetic gastroparesis. Secondly, North America is home to advanced
healthcare infrastructure, including well-established pharmaceutical and
medical device industries, facilitating research, development, and access to
innovative treatments.
Major companies operating in Global Diabetic
Gastroparesis Treatment Market are:
- ANI Pharmaceuticals, Inc.
- Evoke Pharma
- Janssen Pharmaceutica N.V
- Teva Pharmaceuticals Inc.
- Pfizer Inc.
- Salix Pharmaceuticals, Inc.
- Allergan
- Novartis AG
- SCHWITZ BIOTECH
- Wellona Pharma
Download
Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Global
Diabetic Gastroparesis Treatment Market is poised for substantial growth in the
coming years, driven by several key factors. Firstly, the steadily rising
prevalence of diabetes worldwide is contributing to an increased pool of
potential gastroparesis patients. As diabetes remains a significant risk factor
for gastroparesis development, this expanding patient population is expected to
fuel demand for treatment options. Secondly, ongoing research and development
efforts are leading to the introduction of innovative pharmaceuticals and
medical devices tailored to address the unique challenges of diabetic
gastroparesis. These advancements offer more effective and patient-centric
treatment alternatives, attracting both healthcare providers and patients.
Besides, the emphasis on personalized medicine and a multidisciplinary approach
to care is expected to optimize treatment outcomes and enhance patient
satisfaction.” said Mr. Karan Chechi, Research Director with TechSci Research,
a research-based management consulting firm.
“Diabetic Gastroparesis Treatment Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By
Type (Grade 2(Compensated Gastroparesis), Grade 3(Gastric Failure), By Drug
Class (Gastroprokinetic Agents, Antiemetic Agents, Antihistamines, Others), By
Route of Administration (Oral, Parenteral, Nasal), By Distribution Channel
(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) By Region and
Competition”, has evaluated the future growth potential of Global Diabetic
Gastroparesis Treatment Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Diabetic
Gastroparesis Treatment Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com